37 results on '"Nagaraju K"'
Search Results
2. P263 Targeting the innate immune system to block acute inflammatory responses and increase AAV viral transduction of skeletal muscle in mdx mice
3. AUTOIMMUNE & INFLAMMATORY NMD
4. DMD – ANIMAL MODELS & PRECLINICAL TREATMENT
5. P.338Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
6. AUTOIMMUNE & INFLAMMATORY NMD: EP.02 A window into intracellular events in myositis muscle through targeted proteomics
7. REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS
8. DMD CLINICAL THERAPIES I
9. NEW THERAPEUTIC APPROACHES AND THEIR READOUT
10. Epigenetic regulation of a mitochondrial apoptosis mediator, harakiri in maintaining muscle membrane stability in autoimmune myositis
11. Success of preclinical drug trials using reliable and reproducible endpoints in mouse models of neuromuscular diseases
12. Vision DMD: A drug development program for vamorolone in Duchenne muscular dystrophy
13. Vision DMD: Vamorolone drug development program for Duchenne muscular dystrophy
14. Translational development of rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy
15. VISION – DMD: Drug development of VBP15, an experimental steroid-like drug for DMD
16. The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development
17. Development of Rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy
18. Preclinical data for a novel Toll-like receptor antagonist in mdx mice support its clinical development as a potential treatment for disease-related muscle inflammation in Duchenne muscular dystrophy
19. P.309 - Success of preclinical drug trials using reliable and reproducible endpoints in mouse models of neuromuscular diseases
20. EC.O.8 - Epigenetic regulation of a mitochondrial apoptosis mediator, harakiri in maintaining muscle membrane stability in autoimmune myositis
21. D37 - Vision DMD: A drug development program for vamorolone in Duchenne muscular dystrophy
22. G.P.302
23. P.226 - Vision DMD: Vamorolone drug development program for Duchenne muscular dystrophy
24. P.224 - Translational development of rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy
25. P.11.3 Long term treatment with naproxcinod significantly improves skeletal and cardiac function in mdx mouse model of dystrophy
26. P1.56 Submaximal exercise effects on mdx mouse model
27. P4.12 AMPK and PPAR-delta agonists show beneficial effects in the mdx mouse model
28. G.P.356 - Preclinical data for a novel Toll-like receptor antagonist in mdx mice support its clinical development as a potential treatment for disease-related muscle inflammation in Duchenne muscular dystrophy
29. G.P.284 - The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development
30. G.P.254 - VISION – DMD: Drug development of VBP15, an experimental steroid-like drug for DMD
31. G.P.244 - Development of Rimeporide, a sodium-hydrogen exchanger (NHE-1) inhibitor, for patients with Duchenne muscular dystrophy
32. T.I.2 Preclinical drug trial efforts for muscular dystrophy: Methods and end points
33. G.P.10.07 Role of inflammasome in the pathogenesis of dysferlin deficiency
34. G.P.303: Influences on parental decision making about participation in Duchenne and Becker muscular dystrophy clinical trials
35. G.P.302: Perceived barriers and facilitators of participation in clinical trials for Duchenne and Becker muscular dystrophy
36. Modulation of disease severity in mice with targeted disruption of the acid a-glucosidase gene
37. 290P Developing a non-invasive, in vivo method for evaluating muscle inflammation longitudinally in two mouse models of Duchenne muscular dystrophy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.